IL1A and congenital rubella syndrome: (62) As murine models of CAR T-associated toxicities have implied IL-1 as an important pathophysiologic mediator of both CRS and ICANS, the IL-1 receptor antagonist anakinra, which is approved for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease, has become increasingly used for the treatment of refractory toxicity.